Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Stock analysts at HC Wainwright reduced their Q1 2025 EPS estimates for Harmony Biosciences in a research note issued on Monday, April 28th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of $0.78 for the quarter, down from their previous forecast of $0.91. HC Wainwright currently has a "Buy" rating and a $70.00 target price on the stock. The consensus estimate for Harmony Biosciences' current full-year earnings is $2.43 per share. HC Wainwright also issued estimates for Harmony Biosciences' Q2 2025 earnings at $0.90 EPS and FY2025 earnings at $3.85 EPS.
Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.59 by $0.19. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business had revenue of $184.73 million for the quarter, compared to analysts' expectations of $184.26 million. During the same quarter in the previous year, the company earned $0.67 EPS. The business's quarterly revenue was up 19.5% compared to the same quarter last year.
Other research analysts have also issued research reports about the company. Mizuho boosted their target price on Harmony Biosciences from $42.00 to $44.00 and gave the company an "outperform" rating in a research report on Tuesday, March 18th. Deutsche Bank Aktiengesellschaft initiated coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They issued a "buy" rating and a $55.00 price objective on the stock. Needham & Company LLC reiterated a "buy" rating and set a $49.00 target price on shares of Harmony Biosciences in a research report on Tuesday. Finally, UBS Group reduced their price target on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Monday, April 28th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Harmony Biosciences currently has an average rating of "Buy" and a consensus price target of $52.33.
Read Our Latest Report on HRMY
Harmony Biosciences Trading Up 4.3 %
Shares of NASDAQ HRMY traded up $1.28 during trading hours on Thursday, hitting $31.24. 677,209 shares of the company traded hands, compared to its average volume of 576,407. The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of 14.79, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82. The company's 50 day moving average price is $31.34 and its 200 day moving average price is $34.04. Harmony Biosciences has a 12 month low of $26.47 and a 12 month high of $41.61. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in HRMY. Hillsdale Investment Management Inc. raised its holdings in Harmony Biosciences by 0.4% in the fourth quarter. Hillsdale Investment Management Inc. now owns 68,000 shares of the company's stock worth $2,340,000 after purchasing an additional 300 shares in the last quarter. Aurora Investment Counsel grew its position in shares of Harmony Biosciences by 0.6% in the 1st quarter. Aurora Investment Counsel now owns 61,667 shares of the company's stock worth $2,047,000 after buying an additional 374 shares during the last quarter. O Shaughnessy Asset Management LLC lifted its position in Harmony Biosciences by 2.1% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 20,450 shares of the company's stock valued at $704,000 after acquiring an additional 420 shares during the last quarter. GAMMA Investing LLC grew its holdings in Harmony Biosciences by 92.6% in the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company's stock worth $31,000 after purchasing an additional 436 shares during the last quarter. Finally, Rhumbline Advisers increased its position in shares of Harmony Biosciences by 0.4% during the first quarter. Rhumbline Advisers now owns 109,073 shares of the company's stock worth $3,620,000 after purchasing an additional 485 shares in the last quarter. 86.23% of the stock is currently owned by institutional investors.
About Harmony Biosciences
(
Get Free Report)
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
See Also
Before you consider Harmony Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.
While Harmony Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
